SHTPY.US SCHOTT Pharma AG & Co. KGaA
- Market cap
- USD 3.95B
- P/E
- 25.2x
- P/B
- 3.59x
- ROE
- 15.6%
- Dividend yield
- 0.81%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Apr 2026.
Is SHTPY.US undervalued?
Graham numberSHTPY.US trades 100.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SCHOTT Pharma AG & Co. KGaA fundamental analysis
No fundamental analysis for SCHOTT Pharma AG & Co. KGaA yet.
SCHOTT Pharma AG & Co. KGaA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatm…
Full company profileSCHOTT Pharma AG & Co. KGaA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Apr 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SCHOTT Pharma AG & Co. KGaA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.97B | 3.14B | 3.46B | 4.37B | 649M | 821M | 899M | 957M | 986M | 1.13B |
| Gross Profit | 217M | 235M | 263M | 290M | 226M | 296M | 316M | 323M | 332M | 346M |
| Operating Income | 70.3M | 78.2M | 87.9M | 101M | 115M | 169M | 171M | 190M | 187M | 196M |
| EBITDA | - | - | - | - | - | 216M | 245M | 262M | 287M | 309M |
| Net Income | 53.5M | 52.8M | 50.5M | 53.2M | 101M | 125M | 152M | 150M | 146M | 155M |
| EPS | - | - | - | - | 0.67 | 0.83 | 1.01 | 0.99 | 0.97 | 1.03 |
| Balance Sheet | ||||||||||
| Total Assets | 945M | 1.06B | 1.11B | 1.12B | 740M | 1.20B | 1.23B | 1.44B | 1.60B | 1.69B |
| Total Liabilities | 366M | 483M | 555M | 580M | 320M | 487M | 540M | 650M | 705M | 696M |
| Shareholders' Equity | 579M | 573M | 554M | 539M | 419M | 709M | 692M | 792M | 894M | 996M |
| Cash & Short-term Investments | 67.5M | 34.3M | 17.4M | 24.4M | 27.9M | 28.8M | 24.4M | 23.2M | 22.5M | 24.9M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 79.6M | 61.3M | 32.2M | 146M | 132M | 182M | 182M | 225M | 180M | 182M |
| Capital Expenditure | 7.29M | 10.1M | 6.33M | 25.2M | 98.6M | 153M | 176M | 145M | 145M | 130M |
| Free Cash Flow | - | - | - | - | 33.6M | 29.4M | 6.13M | 79.5M | 35.2M | 52.7M |
| Ratios | ||||||||||
| ROE | 9.2% | 9.2% | 9.1% | 9.9% | 24.0% | 17.7% | 21.9% | 18.9% | 16.4% | 15.6% |
| ROA | 5.7% | 5.0% | 4.6% | 4.8% | 13.6% | 10.5% | 12.3% | 10.4% | 9.2% | 9.2% |
| Net Profit Margin | 1.8% | 1.7% | 1.5% | 1.2% | 15.5% | 15.3% | 16.9% | 15.6% | 14.9% | 13.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SCHOTT Pharma AG & Co. KGaA dividends
- Dividend yield
- 0.81%
- Forward dividend
- 0.05 USD
- Payout ratio
- 16.5%
- Ex-dividend date
- Feb 5, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | EUR 24.1M | 0.16 | 16.5% |
| 2025 | EUR 22.6M | 0.15 | 15.1% |
| 2024 | EUR 18.9M | 0.13 | 12.4% |
| 2023 | EUR 11.5M | 0.08 | 9.1% |
| 2022 | EUR 39.8M | 0.26 | 39.5% |
| 2017 | USD 59.3M | - | 111.6% |
| 2016 | USD 43.5M | - | 86.1% |
| 2015 | USD 22.5M | - | 42.6% |
| 2014 | USD 45.7M | - | 85.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns SCHOTT Pharma AG & Co. KGaA
Ownership data of SCHOTT Pharma AG & Co. KGaA is not available yet.
SCHOTT Pharma AG & Co. KGaA company profile
- Company name
- SCHOTT Pharma AG & Co. KGaA
- Ticker
- SHTPY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Employees
- 5,002
- Fiscal year end
- January
- Address
- Hattenbergstrasse 10, Mainz, Germany, 55122
- Phone
- 49 6131 66 0
- Website
- schott-pharma.com
About SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
SCHOTT Pharma AG & Co. KGaA management
3- Mr. Tobias ErfurthHead of Investor Relations
- Isabelle JeangoudouxHead of Global Product Management
- Dr. Arne KlokeHead of Service & Sustainability Management